Advanced Intellectual Property Strategies for Defending Your Life Sciences IPO
The Deal's 2nd half M&A scene: Interview with Spencer Klein, Morrison Foerster
Innovative Exit Strategies for Life Sciences Companies – Interview with Bill Whelan, Member, Mintz Levin
Financing Trends in Life Sciences – Interview with Bill Whelan, Member, Mintz Levin
Polsinelli Podcast - Emerging Technology & Startup Companies
Digital Health: Where is the Action for Entrepreneurs?
The European Medicine Agency’s (EMA) Policy on Publication of Clinical Data for Medicinal Products for Human Use (“EMA Policy”)is now effective as of January 1, 2015. Across the Atlantic, the U.S. Institute of Medicine (IOM)...more
Last week I had the honor of speaking at the 27th Annual Pharmaceutical/Chemical Patent Practice Update put on by the New Jersey Intellectual Property Law Association’s Chemical Practice Committee. The entire program was...more
We are pleased to provide a collection of commentaries on the critical legal issues facing our clients in 2013.
There is hope that global economic and market conditions will continue to improve despite ongoing...more
On 12 January 2012, the Court of Justice of the European Union heard AstraZeneca's appeal of the General Court's judgment largely upholding the European Commission's decision fining AstraZeneca €60 million for abuse of...more
Back to Top